Pharmacological manipulation of brain glycogenolysis as a therapeutic approach to cerebral ischemia.
Brain ischemia resulting from multiple disease states including cardiac arrest, stroke and traumatic brain injury, is a leading cause of death and disability. Despite significant resources dedicated to developing pharmacological interventions, few effective therapeutic options are currently available. The basic consequence of cerebral ischemia, characterized by energy failure and subsequent brain metabolic abnormalities, enables the protective effects by pharmacological manipulation of brain metabolism. We present here the important roles of brain glycogen metabolism and propose inhibition of glycogenolysis as a therapeutic approach to cerebral ischemia.
Xu
Li
L
Center for Drug Discovery, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, China.
Sun
Hongbin
H
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002545:Brain Ischemia / Q000188:drug therapy* / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D050261:Glycogenolysis / Q000187:drug effects*; D007211:Indoles / Q000737:chemistry / Q000627:therapeutic use; D008278:Magnesium Sulfate / Q000737:chemistry / Q000627:therapeutic use; D010654:Phenylbutyrates / Q000737:chemistry / Q000627:therapeutic use; D014315:Triterpenes / Q000737:chemistry / Q000627:therapeutic use; D009828:Oleanolic Acid / Q000031:analogs & derivatives
D006003:Glycogen; D007211:Indoles; D008278:Magnesium Sulfate; D010654:Phenylbutyrates; D014315:Triterpenes; C504712:3-(5-chloroindole-2-carbonyl)amino-2-hydroxy-4-phenylbutyric acid N-methyl-N-methoxyamide; C412811:maslinic acid; D009828:Oleanolic Acid